Metabolic Cross-talk Within the Bone Marrow Milieu: Focus on Multiple Myeloma

Overview

Journal Exp Hematol Oncol

Publisher Biomed Central

Specialty Hematology

Date 2022 Sep 1

PMID 36050788

Authors

Inge Oudaert

Arne Van der Vreken

Anke Maes

Elke de Bruyne

Kim de Veirman

Karin Vanderkerken

Eline Menu

Affiliations

Soon will be listed here.

Abstract

Cancer cells are well-known for their capacity to adapt their metabolism to their increasing energy demands which is necessary for tumor progression. This is no different for Multiple Myeloma (MM), a hematological cancer which develops in the bone marrow (BM), whereby the malignant plasma cells accumulate and impair normal BM functions. It has become clear that the hypoxic BM environment contributes to metabolic rewiring of the MM cells, including changes in metabolite levels, increased/decreased activity of metabolic enzymes and metabolic shifts. These adaptations will lead to a pro-tumoral environment stimulating MM growth and drug resistance In this review, we discuss the identified metabolic changes in MM and the BM microenvironment and summarize how these identified changes have been targeted (by inhibitors, genetic approaches or deprivation studies) in order to block MM progression and survival.

Citing Articles

Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer.

Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J Acta Pharm Sin B. 2024; 14(3):953-1008.

PMID: 38487001 PMC: 10935242. DOI: 10.1016/j.apsb.2023.12.003.

FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway.

Wu H, Qian J, Zhou L, Hu T, Zhang Y, Wang C Aging (Albany NY). 2024; 16(5):4811-4831.

PMID: 38460944 PMC: 10968680. DOI: 10.18632/aging.205634.

Lipid metabolic vulnerabilities of multiple myeloma.

Torcasio R, Gallo Cantafio M, Ikeda R, Ganino L, Viglietto G, Amodio N Clin Exp Med. 2023; 23(7):3373-3390.

PMID: 37639069 PMC: 10618328. DOI: 10.1007/s10238-023-01174-2.

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.

Wang Y, Muylaert C, Wyns A, Vlummens P, de Veirman K, Vanderkerken K Haematologica. 2023; 109(1):256-271.

PMID: 37470139 PMC: 10772537. DOI: 10.3324/haematol.2023.282866.

Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment.

Matamala Montoya M, van Slobbe G, Chang J, Zaal E, Berkers C Front Oncol. 2023; 13:1155621.

PMID: 37091139 PMC: 10117897. DOI: 10.3389/fonc.2023.1155621.

References

Frassanito M, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S . Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia. 2015; 30(3):640-8. DOI: 10.1038/leu.2015.289. View

Liu Q, Luo Q, Halim A, Song G . Targeting lipid metabolism of cancer cells: A promising therapeutic strategy for cancer. Cancer Lett. 2017; 401:39-45. DOI: 10.1016/j.canlet.2017.05.002. View

Maddocks O, Berkers C, Mason S, Zheng L, Blyth K, Gottlieb E . Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2012; 493(7433):542-6. PMC: 6485472. DOI: 10.1038/nature11743. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Steiner N, Muller U, Hajek R, Sevcikova S, Borjan B, Johrer K . The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. PLoS One. 2018; 13(8):e0202045. PMC: 6086450. DOI: 10.1371/journal.pone.0202045. View

Effenberger M, Bommert K, Kunz V, Kruk J, Leich E, Rudelius M . Glutaminase inhibition in multiple myeloma induces apoptosis MYC degradation. Oncotarget. 2017; 8(49):85858-85867. PMC: 5689652. DOI: 10.18632/oncotarget.20691. View

Soncini D, Minetto P, Martinuzzi C, Becherini P, Fenu V, Guolo F . Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. Blood Adv. 2020; 4(18):4312-4326. PMC: 7509874. DOI: 10.1182/bloodadvances.2020001639. View

Kawano Y, Sasano T, Arima Y, Kushima S, Tsujita K, Matsuoka M . A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells. Biochem Biophys Res Commun. 2021; 587:153-159. DOI: 10.1016/j.bbrc.2021.11.102. View

Whitburn J, Edwards C . Metabolism in the Tumour-Bone Microenvironment. Curr Osteoporos Rep. 2021; 19(5):494-499. PMC: 8551098. DOI: 10.1007/s11914-021-00695-7. View

10.

Koh M, Powis G . Passing the baton: the HIF switch. Trends Biochem Sci. 2012; 37(9):364-72. PMC: 3433036. DOI: 10.1016/j.tibs.2012.06.004. View

11.

Raimondi L, De Luca A, Morelli E, Giavaresi G, Tagliaferri P, Tassone P . MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. Biomed Res Int. 2016; 2016:6504593. PMC: 4736225. DOI: 10.1155/2016/6504593. View

12.

Brinkmann J, Abumrad N, Ibrahimi A, van der Vusse G, Glatz J . New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem J. 2002; 367(Pt 3):561-70. PMC: 1222912. DOI: 10.1042/BJ20020747. View

13.

Matula Z, Mikala G, Lukacsi S, Matko J, Kovacs T, Monostori E . Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells. Cancers (Basel). 2021; 13(14). PMC: 8307863. DOI: 10.3390/cancers13143461. View

14.

Curthoys N, Watford M . Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995; 15:133-59. DOI: 10.1146/annurev.nu.15.070195.001025. View

15.

Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F . NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017; 10(1):17. PMC: 5237262. DOI: 10.1186/s13045-017-0392-4. View

16.

Sun K, Tang S, Hou Y, Xi L, Chen Y, Yin J . Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling. EBioMedicine. 2019; 41:370-383. PMC: 6442874. DOI: 10.1016/j.ebiom.2019.02.025. View

17.

Sousa C, Biancur D, Wang X, Halbrook C, Sherman M, Zhang L . Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016; 536(7617):479-83. PMC: 5228623. DOI: 10.1038/nature19084. View

18.

Chen J, Zaal E, Berkers C, Ruijtenbeek R, Garssen J, Redegeld F . Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation. Cells. 2021; 10(9). PMC: 8465636. DOI: 10.3390/cells10092287. View

19.

Abraham J, Salama N, Azab A . The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 2014; 56(1):26-33. DOI: 10.3109/10428194.2014.907890. View

20.

Ikeda S, Kitadate A, Abe F, Takahashi N, Tagawa H . Hypoxia-inducible KDM3A addiction in multiple myeloma. Blood Adv. 2018; 2(4):323-334. PMC: 5858471. DOI: 10.1182/bloodadvances.2017008847. View